Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Research & Development (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Research & Development for 3 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 52.47% to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Dec 2025, down 15.12% year-over-year, with the annual reading at $17.8 million for FY2025, 15.12% down from the prior year.
  • Research & Development for Q4 2025 was $4.2 million at Mereo BioPharma, down from $4.3 million in the prior quarter.
  • The five-year high for Research & Development was $8.8 million in Q4 2024, with the low at $3.2 million in Q3 2024.
  • Average Research & Development over 3 years is $4.7 million, with a median of $4.2 million recorded in 2025.
  • The sharpest move saw Research & Development skyrocketed 83.62% in 2024, then tumbled 52.47% in 2025.
  • Over 3 years, Research & Development stood at $4.8 million in 2023, then surged by 83.62% to $8.8 million in 2024, then crashed by 52.47% to $4.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $4.2 million, $4.3 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.